NovoCure (NASDAQ:NVCR) Shares Gap Up Following Earnings Beat

Shares of NovoCure Limited (NASDAQ:NVCR) gapped up prior to trading on Friday following a stronger than expected earnings report. The stock had previously closed at $19.99, but opened at $20.68. NovoCure shares last traded at $19.6050, with a volume of 406,982 shares changing hands.

The medical equipment provider reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.20. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.02%. The business had revenue of $183.58 million during the quarter, compared to analyst estimates of $172.44 million. During the same period in the previous year, the business earned ($0.36) EPS. NovoCure’s revenue was up 15.6% compared to the same quarter last year.

NovoCure News Summary

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: NovoCure reported Q2 EPS of -$0.13, beating the consensus loss estimate of -$0.33, while revenue came in at $183.6 million versus expectations of $172.4 million. Revenue also rose 15.6% year over year, signaling improving business momentum.
• Positive Sentiment: The company raised its FY2026 revenue guidance to $710 million-$725 million, above the market’s prior expectation of about $704 million, which suggests management sees continued demand strength.
• Positive Sentiment: HC Wainwright increased its price target on NovoCure to $52 from $46 and maintained a Buy rating, reinforcing optimism around the company’s longer-term earnings potential. Article Title
• Neutral Sentiment: Wedbush also raised its price target to $20 from $18, but kept a Neutral rating, indicating improved expectations without a strong bullish call. Article Title
• Neutral Sentiment: Shares also got a lift from optimism around the company’s brain therapy pipeline and possible FDA-related catalysts, which helped push the stock to new highs as investors priced in further upside. Article Title
• Negative Sentiment: HC Wainwright trimmed its FY2029 EPS estimate slightly to $1.90 from $1.95, a small caution on the company’s very long-term earnings outlook.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. HC Wainwright set a $32.00 price target on NovoCure in a research report on Friday. JPMorgan Chase & Co. initiated coverage on NovoCure in a report on Monday, July 13th. They set a “neutral” rating and a $17.00 price objective on the stock. Zacks Research downgraded NovoCure from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Wells Fargo & Company lifted their target price on NovoCure from $13.50 to $17.00 and gave the company an “equal weight” rating in a report on Monday, May 4th. Finally, Weiss Ratings upgraded NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $21.20.

Insider Transactions at NovoCure

In other news, Director Jeryl L. Hilleman sold 2,945 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total transaction of $46,442.65. Following the completion of the transaction, the director directly owned 13,861 shares in the company, valued at $218,587.97. The trade was a 17.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director W Anthony Vernon sold 2,945 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the sale, the director owned 197,657 shares in the company, valued at $3,117,050.89. This trade represents a 1.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 51,943 shares of company stock worth $893,171. 5.52% of the stock is owned by corporate insiders.

Institutional Trading of NovoCure

Institutional investors and hedge funds have recently modified their holdings of the business. Morgan Stanley boosted its position in shares of NovoCure by 453.4% during the 4th quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider’s stock valued at $65,554,000 after acquiring an additional 4,153,741 shares during the last quarter. Soleus Capital Management L.P. increased its position in shares of NovoCure by 25.0% in the second quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock worth $122,897,000 after purchasing an additional 1,382,888 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of NovoCure by 1,093.2% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,223,755 shares of the medical equipment provider’s stock worth $15,823,000 after purchasing an additional 1,121,192 shares during the last quarter. SG Americas Securities LLC raised its stake in NovoCure by 346.7% in the first quarter. SG Americas Securities LLC now owns 1,245,541 shares of the medical equipment provider’s stock valued at $13,576,000 after purchasing an additional 966,735 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in NovoCure in the fourth quarter valued at approximately $11,991,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure Trading Down 11.7%

The firm has a market capitalization of $2.04 billion, a P/E ratio of -13.58 and a beta of 0.94. The company has a quick ratio of 2.70, a current ratio of 2.90 and a debt-to-equity ratio of 0.71. The firm’s 50-day simple moving average is $16.64 and its 200-day simple moving average is $14.14.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.